INS and metabolic dysfunction-associated steatohepatitis: Incretin mimetics, as glucagon-like peptide 1 (GLP-1) receptor agonists (exenatide and liraglutide), increase insulin sensitivity, lower postprandial glucagon levels, and induce weight loss.133–135 Liraglutide may improve hepatic steatosis,136 and in Liraglutide Efficacy and Action in Non-alcoholic steatohepatitis (LEAN) trial was able to resolve biopsy-proven NASH in 39% of the treated patients.